Tetrandrine exerts antidepressant-like effects in animal models: Role of brain-derived neurotrophic factor

Behavioural Brain Research

Volumn 238, Issue 1, 2013, Pages 79-85

  Gao, Shan ^a   Cui, Yuan Lu ^a   Yu, Chun Quan ^a   Wang, Qiang Song ^a   Zhang, Ye ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Antidepressant; Brain derived neurotrophic factor; Neurotransmitter; Tetrandrine; Traditional Chinese Medicine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; MESSENGER RNA; NORADRENALIN; SEROTONIN; TETRANDRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FORCED SWIMMING TEST; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HYPOTHERMIA; IMMOBILIZATION; MALE; MONOAMINERGIC SYSTEM; MOUSE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PTOSIS; RAT; SEROTONIN BRAIN LEVEL; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZYLISOQUINOLINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HINDLIMB SUSPENSION; HIPPOCAMPUS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84868556071     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.10.015     Document Type: Article

References (38)

1. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews Neuroscience 2006, 7:137-151.
2. Belmaker R.H., Agam G. Major depressive disorder. New England Journal of Medicine 2008, 358:55-68.
3. Xu Y., Ku B., Tie L., Yao H., Jiang W., Ma X., et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Research 2006, 1122:56-64.
4. Thachil A.F., Mohan R., Bhugra D. The evidence base of complementary and alternative therapies in depression. Journal of Affective Disorder 2007, 97:23-35.
5. Wurglics M., Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clinical Pharmacokinetics 2006, 45:449-468.
6. Kulkarni S.K., Dhir A. Current investigational drugs for major depression. Expert Opinion on Investigational Drugs 2009, 18:767-788.
7. Tian J.S., Cui Y.L., Hu L.M., Gao S., Chi W., Dong T.J., et al. Antidepressant-like effect of genipin in mice. Neuroscience Letters 2010, 479:236-239.
8. Kwan C.Y., Achike F.I. Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. Acta Pharmacologica Sinica 2002, 23:1057-1068.
9. Xie Q.M., Tang H.F., Chen J.Q., Bian R.L. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacologica Sinica 2002, 23:1107-1113.
10. Shen D.F., Tang Q.Z., Yan L., Zhang Y., Zhu L.H., Wang L., et al. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. British Journal of Pharmacology 2010, 159:970-981.
11. He F.Q., Qiu B.Y., Zhang X.H., Li T.K., Xie Q., Cui D.J., et al. Tetrandrine attenuates spatial memory impairment and hippocampal neuroinflammation via inhibiting NF-kappaB activation in a rat model of Alzheimer's disease induced by amyloid-beta(1-42). Brain Research 2011, 1384:89-96.
12. Fu L., Liang Y., Deng L., Ding Y., Chen L., Ye Y., et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemotherapy Pharmacology 2004, 53:349-356.
13. Zhu X., Sui M., Fan W. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Research 2005, 25:1953-1962.
14. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Archives of International Pharmacodynamics and Therapy 1977, 229:327-336.
15. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. The effects of curcumin on depressive-like behaviors in mice. European Journal of Pharmacology 2005, 518:40-46.
16. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nature Reviews Drug Discovery 2005, 4:775-790.
17. Herrera-Ruiz M., García-Beltrán Y., Mora S., Díaz-Véliz G., Viana G.S., Tortoriello J., et al. Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans. Journal of Ethnopharmacology 2006, 107:53-58.
18. Sánchez-Mateo C.C., Bonkanka C.X., Prado B., Rabanal R.M. Antidepressant activity of some Hypericum reflexum L. fil. extracts in the forced swimming test in mice. Journal of Ethnopharmacology 2007, 112:115-121.
19. Dhir A., Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. European Journal of Pharmacology 2007, 568:177-185.
20. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berlin) 1987, 93:358-364.
21. De Gois S., Schafer M.K., Defamie N., Chen C., Ricci A., Weihe E., et al. Homeostatic scaling of vesicular glutamate and GABA transporter expression in rat neocortical circuits. Journal of Neuroscience 2005, 25:7121-7133.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
23. Willner P. The validity of animal models of depression. Psychopharmacology (Berlin) 1984, 83:1-16.
24. de Klerk O.L., Bosker F.J., Willemsen A.T., Van Waarde A., Visser A.K., de Jager T., et al. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. Journal of Psychopharmacology 2010, 24:1237-1242.
25. Bianchi M., Fone K.C., Shah A.J., Atkins A.R., Dawson L.A., Heidbreder C.A., et al. Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. European Neuropsychopharmacology 2009, 19:778-790.
26. Fuchs E., Czeh B., Kole M.H., Michaelis T., Lucassen P.J. Alterations of neuroplasticity in depression: the hippocampus and beyond. European Neuropsychopharmacology 2004, 14(Suppl. 5):S481-S490.
27. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacology Bulletin 2001, 35:5-49.
28. Yuluĝ B., Ozan E., Gönül A.S., Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Research Bulletin 2009, 78:267-269.
29. Li N., He X., Qi X., Zhang Y., He S. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor. Journal of Psychopharmacology 2010, 24:1772-1778.
30. Cui J., Xiang H. Ginsenoside Rb3 exerts antidepressant-like effects in several animal models. Journal of Psychopharmacology 2011, 26:1-17. [accessed 24.09.11].
31. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Medicine 2004, 5:11-25.
32. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry 2001, 50:260-265.
33. De Foubert G., Carney S.L., Robinson C.S., Destexhe E.J., Tomlinson R., Hicks C.A., et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004, 128:597-604.
34. Molteni R., Calabrese F., Bedogni F., Tongiorgi E., Fumagalli F., Racagni G., et al. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. International Journal of Neuropsychopharmacology 2006, 9:307-317.
35. Ayensu W.K., Pucilowski O., Mason G.A., Overstreet D.H., Rezvani A.H., Janowsky D.S. Effects of chronic mild stress on serum complement activity, saccharin preference, and corticosterone levels in Flinders lines of rats. Physiology and Behavior 1995, 57:165-169.
36. Grippo A.J., Francis J., Beltz T.G., Felder R.B., Johnson A.K. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. Physiology and Behavior 2005, 84:697-706.
37. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
38. Bourin M., Poncelet M., Chermat R., Simon P. The value of the reserpine test in psychopharmacology. Arzneimittelforschung 1983, 33:1173-1176.